Trials / Completed
CompletedNCT03383887
DAW1033D in Obstructive Sleep Apnea
Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033D administered before sleep on OSA phenotype traits and OSA severity during sleep.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo oral capsule | Placebo before sleep |
| DRUG | DAW1033D oral capsule | DAW1033D before sleep |
Timeline
- Start date
- 2017-12-13
- Primary completion
- 2020-01-20
- Completion
- 2020-01-20
- First posted
- 2017-12-27
- Last updated
- 2020-02-25
- Results posted
- 2020-02-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03383887. Inclusion in this directory is not an endorsement.